Related Experiment Videos
Alpha1-antichymotrypsin in rheumatoid arthritis
The Tohoku Journal of Experimental Medicine
|August 1, 1976
Summary
Serum alpha1-antichymotrypsin (alpha1-ACT) is significantly elevated in rheumatoid arthritis patients, correlating with other acute phase proteins like CRP. Oral alpha-chymotrypsin did not affect alpha1-ACT levels or disease markers.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory disease.
- Acute phase proteins are biomarkers of inflammation.
- Alpha1-antichymotrypsin (alpha1-ACT) role in RA requires further investigation.
Purpose of the Study:
- To investigate serum alpha1-antichymotrypsin (alpha1-ACT) levels in rheumatoid arthritis (RA).
- To explore correlations between alpha1-ACT and other acute phase proteins and clinical markers in RA.
- To assess the effect of oral alpha-chymotrypsin on alpha1-ACT in RA patients.
Main Methods:
- Single radial immunodiffusion was used to quantify serum alpha1-ACT.
- Correlations were analyzed between alpha1-ACT, alpha1-acid glycoprotein, alpha1-antitrypsin, and C-reactive protein (CRP).
- Fibrinolytic activity and clinical indices were also assessed.
Main Results:
- Serum alpha1-ACT concentrations were significantly elevated in RA patients.
- Positive correlations were found between alpha1-ACT and other glycoproteins (alpha1-acid glycoprotein, alpha1-antitrypsin) and CRP.
- An inverse correlation was observed between alpha1-ACT and fibrinolytic activity.
- Oral alpha-chymotrypsin administration showed no significant effect on alpha1-ACT levels or clinical/articular indices.
Conclusions:
- Alpha1-ACT functions as an acute phase protein in rheumatoid arthritis.
- Alpha1-ACT levels are linked to inflammatory processes and fibrinolytic activity in RA.
- Therapeutic administration of oral alpha-chymotrypsin is ineffective in modulating alpha1-ACT in RA.